Multifunctional nucleic acids for tumor cell treatment

Nucleic Acid Therapeutics

Volumn 24, Issue 2, 2014, Pages 171-177

  Pofahl, Monika ^a   Wengel, Jesper ^b   Mayer, Günter ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAGOMIR; ANTIMIR 21; APTAMER; APTAMIR; APTAMIR 21; AS 1411; MICRORNA; MICRORNA 21; NUCLEIC ACID; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GENE THERAPY; CELL SPECIFICITY; CONTROLLED STUDY; DRUG TARGETING; GENE EXPRESSION; GENE INDUCTION; GENE SILENCING; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APTAMERS, NUCLEOTIDE; BASE SEQUENCE; CELL LINE, TUMOR; CELL SURVIVAL; GENE SILENCING; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HUMANS; MICRORNAS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; OLIGONUCLEOTIDES; RECOMBINANT FUSION PROTEINS;

EID: 84896972716     PISSN: 21593337     EISSN: None     Source Type: Journal    
DOI: 10.1089/nat.2013.0472     Document Type: Article

References (24)

1. BATES, P. J., LABER, D. A., MILLER, D. M., THOMAS, S. D., and TRENT, J. O. (2009). Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer. Exp. Mol. Pathol. 86, 151-164.
2. CHO, W. C. (2007). OncomiRs: the discovery and progress of microRNAs in cancers. Mol. Cancer 6, 60.
3. CHU, T. C., MARKS, J. W., 3rd, LAVERY, L. A., FAULKNER, S., ROSENBLUM, M. G., ELLINGTON, A. D., and LEVY, M. (2006). Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989-5992.
4. ELMEN, J., LINDOW, M., SCHUTZ, S., LAWRENCE, M., PETRI, A., OBAD, S., LINDHOLM, M., HEDTJARN, M., HANSEN, H. F., BERGER, U., et al. (2008). LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899.
5. FAROKHZAD, O. C., CHENG, J., TEPLY, B. A., SHERIFI, I., JON, S., KANTOFF, P. W., RICHIE, J. P., and LANGER, R. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl. Acad. Sci. U. S. A. 103, 6315-6320.
6. KANASTY, R. L., WHITEHEAD, K. A., VEGAS, A. J., and ANDERSON, D. G. (2012). Action and Reaction: The Biological Response to siRNA and Its Delivery Vehicles. Mol. Ther. 20,513-524.
7. KRICHEVSKY, A. M., and GABRIELY, G. (2009). miR-21: a small multi-faceted RNA. J. Cell Mol. Med. 13, 39-53.
8. LANFORD, R. E., HILDEBRANDT-ERIKSEN, E. S., PETRI, A., PERSSON, R., LINDOW, M., MUNK, M. E., KAUPPINEN, S., and ORUM, H. (2010). Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327, 198-201.
9. LIM, L. P., GLASNER, M. E., YEKTA, S., BURGE, C. B., and BARTEL, D. P. (2003). Vertebrate microRNA genes. Science 299, 1540.
10. LOU, Y., CUI, Z., WANG, F., YANG, X., and QIAN, J. (2011). miR-21 down-regulation promotes apoptosis and inhibits invasion and migration abilities of OVCAR3 cells. Clin. Invest. Med. 34, E281.
11. MALIK, R., and ROY, I. (2011). Making sense of therapeutics using antisense technology. Expert Opin. Drug Discov. 6, 507-526.
12. MAYER, G. (2009). The chemical biology of aptamers. Angew Chem. Int. Ed. Engl. 48, 2672-2689.
13. MAYER, G., AHMED, M. S., DOLF, A., ENDL, E., KNOLLE, P. A., and FAMULOK, M. (2010). Fluorescence-activated cell sorting for aptamer SELEX with cell mixtures. Nat. Protoc. 5, 1993-2004.
14. MCNAMARA, J. O., 2nd, ANDRECHEK, E. R., WANG, Y., VILES, K. D., REMPEL, R. E., GILBOA, E., SULLENGER, B. A., and GIANGRANDE, P. H. (2006). Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 24, 1005-1015.
15. MONGELARD, F., and BOUVET, P. (2010). AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 12, 107-114.
16. OBAD, S., DOS SANTOS, C. O., PETRI, A., HEIDENBLAD, M., BROOM, O., RUSE, C., FU, C., LINDOW, M., STENVANG, J., STRAARUP, E. M., et al. (2011). Silencing of microRNA families by seed-targeting tiny LNAs. Nat. Genet. 43, 371-378.
17. REYES-REYES, E. M., TENG, Y., and BATES, P. J. (2010). A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolindependent mechanism. Cancer Res. 70, 8617-8629.
18. SEFAH, K., SHANGGUAN, D., XIONG, X., O'DONOGHUE, M. B., and TAN, W. (2010). Development of DNA aptamers using Cell-SELEX. Nat. Protoc. 5, 1169-1185.
19. SOUNDARARAJAN, S., CHEN, W., SPICER, E. K., COURTENAY-LUCK, N., and FERNANDES, D. J. (2008). The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in human breast cancer cells. Cancer Res. 68, 2358-2365.
20. STEIN, C. A., HANSEN, J. B., LAI, J., WU, S., VOSKRESENSKIY, A., HOG, A., WORM, J., HEDTJARN, M., SOULEIMANIAN, N., MILLER, P., et al. (2010). Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38, e3.
21. TENG, Y., GIRVAN, A. C., CASSON, L. K., PIERCE, W. M., JR., QIAN, M., THOMAS, S. D., and BATES, P. J. (2007). AS1411 alters the localization of a complex containing protein arginine methyltransferase 5 and nucleolin. Cancer Res. 67, 10491-10500.
22. TONG, A. W., and NEMUNAITIS, J. (2008). Modulation of miRNA activity in human cancer: a new paradigm for cancer gene therapy? Cancer Gene Ther. 15, 341-355.
23. YAN, L. X., WU, Q. N., ZHANG, Y., LI, Y. Y., LIAO, D. Z., HOU, J. H., FU, J., ZENG, M. S., YUN, J. P., WU, Q. L., et al. (2011). Knockdown of miR-21 in human breast cancer cell lines inhibits proliferation, in vitro migration and in vivo tumor growth. Breast Cancer Res. 13, R2.
24. ZHOU, J., LI, H., ZHANG, J., PIOTR, S., and ROSSI, J. (2011). Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. J. Vis. Exp. 52, 2954.